amiodarone has been researched along with Central Nervous System Disease in 3 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care, in adults who had nontraumatic out-of-hospital cardiac arrest, shock-refractory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular access." | 9.22 | Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. ( Aufderheide, TP; Brienza, AM; Brown, SP; Callaway, CW; Christenson, J; Colella, MR; Daya, M; Desvigne-Nickens, P; Dorian, P; Dunford, JV; Egan, D; Gray, PC; Gray, R; Idris, AH; Kudenchuk, PJ; Leroux, B; Morrison, LJ; Nichol, G; Ornato, JP; Rea, T; Seals, N; Stiell, IG; Straight, R; Vaillancourt, C; Vilke, GM; Weisfeldt, ML; Wittwer, L, 2016) |
| "In this randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care, in adults who had nontraumatic out-of-hospital cardiac arrest, shock-refractory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular access." | 5.22 | Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. ( Aufderheide, TP; Brienza, AM; Brown, SP; Callaway, CW; Christenson, J; Colella, MR; Daya, M; Desvigne-Nickens, P; Dorian, P; Dunford, JV; Egan, D; Gray, PC; Gray, R; Idris, AH; Kudenchuk, PJ; Leroux, B; Morrison, LJ; Nichol, G; Ornato, JP; Rea, T; Seals, N; Stiell, IG; Straight, R; Vaillancourt, C; Vilke, GM; Weisfeldt, ML; Wittwer, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudenchuk, PJ | 1 |
| Brown, SP | 1 |
| Daya, M | 1 |
| Rea, T | 1 |
| Nichol, G | 1 |
| Morrison, LJ | 1 |
| Leroux, B | 1 |
| Vaillancourt, C | 1 |
| Wittwer, L | 1 |
| Callaway, CW | 1 |
| Christenson, J | 1 |
| Egan, D | 1 |
| Ornato, JP | 1 |
| Weisfeldt, ML | 1 |
| Stiell, IG | 1 |
| Idris, AH | 1 |
| Aufderheide, TP | 1 |
| Dunford, JV | 1 |
| Colella, MR | 1 |
| Vilke, GM | 1 |
| Brienza, AM | 1 |
| Desvigne-Nickens, P | 1 |
| Gray, PC | 1 |
| Gray, R | 1 |
| Seals, N | 1 |
| Straight, R | 1 |
| Dorian, P | 1 |
| Le-Nguyen, XT | 1 |
| Lee, TK | 1 |
| Do, DV | 1 |
| Sepah, YJ | 1 |
| Nguyen, QD | 1 |
| Rao, NA | 1 |
| Vasconcelos-Santos, DV | 1 |
| Goldstein, DA | 1 |
| Lubbe, WF | 1 |
| Mercer, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT)[NCT01401647] | Phase 3 | 3,024 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neurologic status at discharge will be assessed using the modified Rankin Score (MRS). A higher value indicates a worse outcome. 0-No symptoms at all; 1-No significant disability despite symptoms; able to carry out all usual duties and activities, 2-Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance, 3-Moderate disability; requiring some help, but able to walk without assistance; 4-Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance, 5-Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6-Dead (NCT01401647)
Timeframe: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
| Intervention | Participants (Count of Participants) |
|---|---|
| Amiodarone | 182 |
| Lidocaine | 172 |
| Normal Saline | 175 |
Patients may die in the field (outside of the hospital at the time of the cardiac arrest), at the emergency room, in the hospital, or they are discharged alive from the hospital. (NCT01401647)
Timeframe: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
| Intervention | participants (Number) |
|---|---|
| Amiodarone | 237 |
| Lidocaine | 233 |
| Normal Saline | 222 |
1 trial available for amiodarone and Central Nervous System Disease
| Article | Year |
|---|---|
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Central Nervous Syst | 2016 |
2 other studies available for amiodarone and Central Nervous System Disease
| Article | Year |
|---|---|
Diagnostic and therapeutic challenges.
Topics: Adult; Amiodarone; Central Nervous System Diseases; Diagnosis, Differential; Glucocorticoids; Humans | 2011 |
Amiodarone: its side effects, adverse reactions and dosage schedules.
Topics: Amiodarone; Benzofurans; Central Nervous System Diseases; Drug Administration Schedule; Eye Diseases | 1982 |